{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:43:26Z","timestamp":1769125406017,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1177,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>ARIADNE aimed to assess the association between effects of sacubitril\/valsartan and no sacubitril\/valsartan treatment and clinical characteristics, functional capacity, and clinical outcomes (cause-specific mortality and hospitalizations) in outpatients with heart failure (HF) with reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ARIADNE was a prospective European registry of 9069 patients with HFrEF treated by office-based cardiologists or selected primary care physicians. Of the 8787 eligible for analysis, 4173 patients were on conventional HF treatment (non-S\/V group), whereas 4614 patients were either on sacubitril\/valsartan treatment at enrolment or started sacubitril\/valsartan within 1 month of enrolment (S\/V group). We also generated a restricted analysis set (rS\/V) including only those 2108 patients who started sacubitril\/valsartan treatment within the month prior to or after enrolment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At the baseline, average age of patients enrolled in the study was 68 years, and 23.9% (2099\/8787) were female. At the baseline, the proportions of patients with New York Heart Association (NYHA) Class III symptoms were 30.9 (1288\/4173), 42.8 (1974\/4614), and 48.2% (1015\/2108), in non-S\/V, S\/V, and rS\/V groups, respectively. After 12 months of treatment, the proportion of patients with NYHA Class III at baseline who improved to Class II was 32.0% (290\/907) in the non-S\/V group vs. 46.3% (648\/1399) in S\/V group and 48.7% (349\/717) in rS\/V group. The overall mortality rate was 5.0 per 100 patient-years. Rates of HF hospitalizations were high (20.9, 20.3, and 21.2 per 100 patient-years in the non-S\/V, S\/V, and rS\/V groups, respectively). Emergency room visits without hospitalization occurred in 3.9, 3.2, and 3.9% of patients in the non-S\/V, S\/V, and rS\/V groups, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This large HFrEF European registry provides a contemporary outcome profile of outpatients with HFrEF treated with or without sacubitril\/valsartan. In a real-world setting, sacubitril\/valsartan was associated with an improvement of symptoms in patients with HFrEF compared with the conventional HFrEF treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14014","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T04:55:56Z","timestamp":1663217756000},"page":"4209-4218","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes with Sacubitril\/Valsartan in Outpatients with Heart Failure and Reduced Ejection Fraction: The ARIADNE Registry"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-6779","authenticated-orcid":false,"given":"Aldo P.","family":"Maggioni","sequence":"first","affiliation":[{"name":"Heart Care Foundation ANMCO Research Centre , Florence ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust , Hull ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[{"name":"University Hospital Ramon y Cajal , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"University Hospital Henri Mondor , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Drozdz","sequence":"additional","affiliation":[{"name":"Medical University of Lodz , Lodz ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candida","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Hospital de Sao Francisco Xavier, Lisbon, NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa , Lisbon ,","place":["Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet and Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Kalus","sequence":"additional","affiliation":[{"name":"GKM Gesellschaft f\u00fcr Therapieforschung mbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe C.","family":"Ferber","sequence":"additional","affiliation":[{"name":"Novartis Pharma , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan I.","family":"Hussain","sequence":"additional","affiliation":[{"name":"Arxx Therapeutics , Oslo ,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Koch","sequence":"additional","affiliation":[{"name":"Novartis Pharma , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[{"name":"Klinikum Ludwigshafen and Institut f\u00fcr Herzinfarktforschung , Ludwigshafen-am-Rhein ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the ARIADNE investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"2026012114134884300_ehf214014-bib-0001","first-page":"3599","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","journal-title":"Eur Heart J 2021"},{"key":"2026012114134884300_ehf214014-bib-0002","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114134884300_ehf214014-bib-0003","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114134884300_ehf214014-bib-0004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ehf2.12569","article-title":"Management of heart failure with reduced ejection fraction in Europe: Design of the ARIADNE registry","volume":"7","author":"Zeymer","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114134884300_ehf214014-bib-0005","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalised or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012114134884300_ehf214014-bib-0006","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ehjqcco\/qcab019","article-title":"Utilisation of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction: Real world data from the ARIADNE registry","volume":"8","author":"Zeymer","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026012114134884300_ehf214014-bib-0007","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114134884300_ehf214014-bib-0008","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis","volume":"33","author":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012114134884300_ehf214014-bib-0009","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction","volume":"1","author":"Kalogeropoulos","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012114134884300_ehf214014-bib-0010","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","journal-title":"Eur J Heart Fail 2019"},{"key":"2026012114134884300_ehf214014-bib-0011","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ejhf.762","article-title":"Association between enrolment in a heart failure quality registry and subsequent mortality-A nationwide cohort study","volume":"19","author":"Lund","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114134884300_ehf214014-bib-0012","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114134884300_ehf214014-bib-0013","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCHEARTFAILURE.112.000161","article-title":"Multicenter prospective observational study on acute and chronic heart failure: One-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry","volume":"6","author":"Tavazzi","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026012114134884300_ehf214014-bib-0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012199","article-title":"Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry","volume":"9","author":"MacDonald","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012114134884300_ehf214014-bib-0015","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC heart failure long-term registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114134884300_ehf214014-bib-0016","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114134884300_ehf214014-bib-0017","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.1038\/s41598-020-63801-2","article-title":"Clinical and echocardiographic benefit of Sacubitril\/valsartan in a real-world population with HF with reduced ejection fraction","volume":"10","author":"Polito","year":"2020","journal-title":"Sci Rep"},{"key":"2026012114134884300_ehf214014-bib-0018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"2026012114134884300_ehf214014-bib-0019","article-title":"Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction","volume":"31","author":"Landolfo","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026012114134884300_ehf214014-bib-0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.23736\/S0026-4725.19.04971-5","article-title":"Sacubitril\/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction","volume":"67","author":"De Vecchis","year":"2019","journal-title":"Minerva Cardioangiol"},{"key":"2026012114134884300_ehf214014-bib-0021","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","article-title":"Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: A systematic review","volume":"331","author":"Proudfoot","year":"2021","journal-title":"Int J Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14014","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/6\/4209\/65347701\/eschf_9_6_4209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/6\/4209\/65347701\/eschf_9_6_4209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:16:01Z","timestamp":1769022961000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/6\/4209\/8322819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,9,15]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14014","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"2022-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}